42nd Annual Miami Breast Cancer Conference® - Abstracts
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
ByAntonio Llombart-Cussac,José Manuel Pérez-García,Elena Lopez-Miranda,Rui Rui Zhang,Miguel Sampayo-Cordero,Juliana Carvalho-Santos,Olga Boix,Marta Beltran,Carlos Barrios,Guiseppe Curigliano,Rupert Bartsch,Anne Clair Hardy Bessard,Anna Compagnoni,Kathy Puyana Theall,Thomas Buechele,Tomer Wasserman,Javier Cortés, MD
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
ByHeather McArthur, MD, MPH,Peter A. Fasching,Rebecca Dent, MD,Javier Cortés, MD,Lajos Pusztai, MD, DPhil,Sherko Kuemmel,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck, MD, PhD,Masato Takahashi,Seock-Ah Im,Michael Untch, MD, PhD,Marie-Ange Mouret-Reynier,Theodoros Foukakis,Marta Ferreira,Fatima Cardoso,Yu Ding,Cecilia Pinheiro,Jaime Mejia,Joyce A. O’Shaughnessy,Peter Schmid, MD
Advertisement
Advertisement
Trending on CancerNetwork
1
177Lu-PSMA-I&T/223Ra Display Safety and Feasibility in Metastatic CRPC
2
H.R. 2541: Examining Its Legislative Impact on Radiopharmaceutical Practice
3
Pembrolizumab Combo Does Not Significantly Improve OS in Unresectable HCC
4
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed PD-L1–Positive Metastatic NSCLC
5
